Latest Breaking News On - தங்கம் உயிரி தொழில்நுட்பவியல் கார்ப் - Page 1 : vimarsana.com
COVID-19 Scoop: Epoch-Making GoldenBiotech s Oral COVID-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
COVID-19 Scoop: Epoch-Making GoldenBiotech s Oral COVID-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients | Taiwan News
taiwannews.com.tw - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from taiwannews.com.tw Daily Mail and Mail on Sunday newspapers.
COVID-19 Scoop: Epoch-Making GoldenBiotech s Oral COVID-19 New Drug Trial Got Green Light from the FDA to Extend Recruiting Severe COVID-19 Patients
asiaone.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from asiaone.com Daily Mail and Mail on Sunday newspapers.
Taiwan Business TOPICS Local pharmaceutical firm Golden Biotechnology Corp. independently developed Antroquinonol
(Hocena®), a novel small-molecule drug, and is now testing its use for treatment of COVID-19. Photo: Golden Biotechnology Corp.
Despite rigorous border control and strict measures, COVID-19 has made its way into Taiwan. Now businesses, researchers, and government are working on innovations that will put Taiwan back in business.
Until recently, Taiwan had a remarkable success record in containing the spread of COVID-19 and maintaining normality for its citizens. While hospitals worldwide had their capacities stretched to their limits, Taiwan reported approximately 1,200 local cases and 11 related deaths in 14 months. However, in May, a few local clusters resulted in a significant spread of the coronavirus around the island.
A drug candidate developed by Golden Biotechnology Corp is to enter phase 2 clinical trials patients in the US for treatment of severely ill COVID-19, pending authorization by the authorities, the Taiwanese drugmaker said.
The drug, called antroquinonol, is undergoing phase 2 clinical trials in the US, Peru and Argentina, where 174 hospital patients with mild to moderate COVID-19 symptoms are enrolled in the double-blind placebo study, the company said in statement on Wednesday last week.
Preliminary results of the phase 2 trials in the US were commended by an independent data monitoring committee assigned to the trials by the US